These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11295630)

  • 1. Trial endpoints for drug approval in oncology: Chemoprevention.
    Beitz J
    Urology; 2001 Apr; 57(4 Suppl 1):213-5. PubMed ID: 11295630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
    McKee AE; Farrell AT; Pazdur R; Woodcock J
    Oncologist; 2010; 15 Suppl 1():13-8. PubMed ID: 20237212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007.
    Sridhara R; Johnson JR; Justice R; Keegan P; Chakravarty A; Pazdur R
    J Natl Cancer Inst; 2010 Feb; 102(4):230-43. PubMed ID: 20118413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated approval of oncology products: the food and drug administration experience.
    Johnson JR; Ning YM; Farrell A; Justice R; Keegan P; Pazdur R
    J Natl Cancer Inst; 2011 Apr; 103(8):636-44. PubMed ID: 21422403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protocol design considerations that relate to demonstrating the safety and effectiveness of chemopreventive agents.
    Johnson KA; Beitz J; Justice R; Schmidt W; Andrews P; DeLap R
    J Cell Biochem Suppl; 1997; 27():1-6. PubMed ID: 9591186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. End points and United States Food and Drug Administration approval of oncology drugs.
    Johnson JR; Williams G; Pazdur R
    J Clin Oncol; 2003 Apr; 21(7):1404-11. PubMed ID: 12663734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncology drug review process.
    Farrell AT; Pazdur R
    J Natl Compr Canc Netw; 2003 Jan; 1(1):109-13. PubMed ID: 19764154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arthritis drug approved for polyp prevention blazes trail for other prevention trials.
    Smigel K
    J Natl Cancer Inst; 2000 Feb; 92(4):297-9. PubMed ID: 10675374
    [No Abstract]   [Full Text] [Related]  

  • 10. New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule.
    Fed Regist; 1992 Dec; 57(239):58942-60. PubMed ID: 10123232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
    Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
    J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated drug approval: FDA may get tougher; companies cite hurdles.
    Goozner M
    J Natl Cancer Inst; 2011 Mar; 103(6):455-7. PubMed ID: 21393609
    [No Abstract]   [Full Text] [Related]  

  • 13. Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA's accelerated approval regulations for disease modifying osteoarthritis drugs.
    Kraus VB; Simon LS; Katz JN; Neogi T; Hunter D; Guermazi A; Karsdal MA
    Osteoarthritis Cartilage; 2019 Apr; 27(4):571-579. PubMed ID: 30465809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The IND application.
    Ferkany JW; Williams M
    Curr Protoc Pharmacol; 2008 Sep; Chapter 9():Unit 9.10. PubMed ID: 22294234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(133):39588-611. PubMed ID: 18850675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Despite positive studies, popularity of chemoprevention drugs increasing slowly.
    Zielinski SL
    J Natl Cancer Inst; 2004 Oct; 96(19):1410-2. PubMed ID: 15467023
    [No Abstract]   [Full Text] [Related]  

  • 19. Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations.
    Lieberman R; Nelson WG; Sakr WA; Meyskens FL; Klein EA; Wilding G; Partin AW; Lee JJ; Lippman SM
    Urology; 2001 Apr; 57(4 Suppl 1):4-27. PubMed ID: 11295590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Food and Drug Administration and pragmatic clinical trials of marketed medical products.
    Anderson ML; Griffin J; Goldkind SF; Zeitler EP; Wing L; Al-Khatib SM; Sherman RE
    Clin Trials; 2015 Oct; 12(5):511-9. PubMed ID: 26374684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.